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Analysis of the complement C3 fragments associated with hemodialysis
membranes. During hemodialysis with cuprophan membranes, bioac-
tive peptides are generated because the alternative pathway of comple-
ment is activated. When cellulose acetate membranes are employed,
complement activation is attenuated. The molecular basis for this
improved biocompatability is unknown. It has been postulated, how-
ever, that the complement activating potential of dialysis membranes is
influenced by the availability of free hydroxyl groups which would
provide an acceptor site for activated C3. To investigate this hypothe-
sis, the forms of C3 associated with cellulose acetate and cuprophan
membranes have been analyzed. By Western blot, the predominant
form of C3 present on both types of membranes is C3c, a degradation
product of C3 that lacks the thiolester necessary for covalent bonding.
Minimal amounts of C3d (the region of C3 which contains the thiolester)
were observed on both membranes; however, by ELISA, there was no
difference in the amount bound to cellulose acetate compared to
cuprophan. Further, membrane-associated C3d could be removed by
urea, suggesting that it was not bound covalently. These studies
indicate that the complement activating potential of dialysis membranes
is not determined primarily by the availability of potential covalent
binding sites for activated C3b.
During hemodialysis with cuprophan membranes, the alter-
native pathway of complement (APC) is activated [1, 2]. Certain
untoward effects of dialysis such as leukopenia [1—5] and
pulmonary artery hypertension [3, 6—8] appear to be mediated
by bioactive peptides (C3a, C5a and CSadesArg) which are
generated as a result of the complement activation [1—5, 8, 91.
Although the biochemical events involved in APC activation by
cuprophan membranes have not been defined, the sequence of
events which results in APC activation on certain other biolog-
ical surfaces has been elucidated at the molecular level [10, 11],
and these observations have suggested a mechanism by which
dialysis membranes may initiate and support APC activity.
Because of low grade spontaneous activation of C3 in plasma,
nascent C3b molecules are continuously generated [12]. The
enzymatic cleavage of anaphylatoxin C3a from native C3 in-
duces conformational changes in nascent C3b such that an
internal thiolester bond (located in the C3d region of the
molecule) becomes exposed [13]. This exposed but intact
thiolester constitutes the labile binding site of C3b. By carbonyl
transfer, metastable C3b can form an oxygen ester or amide
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ester bond with a nearby membrane constituent [14, 15]. If no
binding surface is available, nascent C3b is rapidly hydrolyzed
into an inactive form. The binding of C3b to a membrane
surface creates a nidus for formation of the C3 (C3Bb) and C5
(C3bBbC3b) convertases of the APC. Although the binding of
C3b to surfaces such as zymosan and erythrocytes appears to
be primarily covalent [16, 17], there is no direct evidence that
demonstrates that covalent binding is a requirement for APC
activation. Clearly, initiation and amplification of APC activity
occur in the absence of any particulate substances [10].
The activity of the amplification convertases is regulated by
factor H and factor I, the endogenous control proteins of the
APC. Factor H binds to C3b, thereby displacing the enzymatic
subunit (Bb) of the convertase complex and inhibiting further
binding of factor B. In addition, factor H serves as a cofactor in
the enzymatic degradation of C3b to iC3b by factor I. The iC3b
molecule can then be further cleaved to yield C3c and C3dg
fragments. The biochemical properties of the surface to which
C3b binds greatly influence the affinity of factor H for C3b [11].
For example, zymosan and rabbit erythrocytes spontaneously
activate the human APC because a portion of the C3b molecules
bound to these surfaces has a higher affinity for factor B than for
factor H [181.
Inasmuch as the APC is spontaneously activated during
dialysis with cuprophan membranes, it has seemed plausible to
postulate that these membranes represent a type of activator
surface and that the availability of free hydroxyl groups as a
source of nucleophilic attack on the thiolester carbonyl of
nascent C3b is an essential feature of their complement activat-
ing potential. Several observations have been interpreted as
being consistent with this concept. First, when cuprophan
membranes are reused, they support much less complement
activation than previously unused membranes [4, 5, 19]. This
observation suggests the possibility that during the initial dial-
ysis, the available binding sites for metastable C3b become
occupied, thereby limiting further C3b binding and APC acti-
vation during the reuse. Second, treatment of used cuprophan
dialyzers with sodium hypochlorite regenerates the potential of
the membrane to form anaphylatoxins [20] and to induce
leukopenia [211. These observations are consistent with the
hypothesis that sodium hypochlorite removes proteins which
restrict binding of nascent C3b, thereby restoring the comple-
ment activating potential of the previously used membrane.
Third, cellulose acetate membranes support less complement
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activation than cuprophan membranes [22, 23]. Cuprophan
membranes have a cellulose-based structure with free hydroxyl
groups on the glucose rings. Cellulose acetate membranes are
biochemically similar to cuprophan membranes except that the
majority of the surface hydroxyl groups are substituted with
acetate residues. It has been suggested that the acetylation
attenuates complement activation by blocking the source (the
free hydroxyl groups) of nucleophilic attack on the C3 thiolester
[24].
In order to investigate further the molecular mechanisms
which regulate complement activation on dialysis membranes,
we have analyzed the forms of C3 which are bound to cupro-
phan and cellulose acetate membranes and the effects of treat-
ment with sodium hypochlorite on C3 associated with used
cuprophan membranes. These studies demonstrate that while
sodium hypochiorite does remove C3 from the dialyzers, APC
activation by dialysis membranes does not appear to depend
primarily upon covalent binding of C3b to the membrane.
Further, the difference in the complement activating potential
between cuprophan and cellulose acetate membranes cannot be
explained by quantitative or qualitative differences in mem-
brane-associated C3.
Methods
Buffers and solutions
All chemicals were of a reagent grade. The following buffers
and solutions were employed: bovine serum albumin (BSA;
Sigma Chemical Co., St. Louis, Missouri, USA); phosphate-
buffered saline (PBS), pH 7.4 consisting of 10 m sodium
phosphate, 145 mri NaCI and 0.02% azide; PBS with 0.5% BSA
(PBS/A); PBS-Tween consisting of PBS and 0.05% Tween 20
(Sigma Chemical Co.); Tris-buffered saline (TBS) consisting of
10 mri Tris HC1, pH 7.4 and 145 mrvi NaCI; TBS-milk in which
5% (wt/vol) nonfat dry milk was added to the TBS; 10 M urea
(Matheson Co. Inc., Norwood, Ohio, USA), titrated to pH 7.0
with 5 M NaOH; 1 M hydroxylamine monohydrochloride
(NH2OH; Sigma Chemical Co.) titrated to pH 10.5 with 5 M
NaOH; 4% sodium hypochiorite (NaOCl; Labbco Inc., Hous-
ton, Texas, USA).
Preparation of normal human serum (NHS)
Whole blood was collected from normal human donors in
plastic bags containing citrate (CDPA-1). The plasma was
obtained by centrifugation, pooled, and allowed to clot follow-
ing the addition of 2 mi CaCl2 (final concentration). After
removal of the fibrin clot, the serum was supplemented with 2
m of MgCI2 and stored at 70°C. EDTA-serum contained 20
mM Na2EDTA.
Patient studies
The protocol for the parts of this study that involved human
subjects was approved by the Institutional Review Board of the
School of Medicine, University of Utah. Informed consent was
obtained from all participants. The patients, all of whom had
end-stage renal disease, were undergoing thrice weekly hemo-
dialysis using heparin as the anticoagulant. They had no evi-
dence of intercurrent illness.
Preparation of dialysis membranes
The following types of dialyzers were employed: (1) cupro-
phan hollow fiber (CFI511, surface area 1.1 M2, Travenol
Laboratories, Deerfield, Illinois, USA); and (2) cellulose ace-
tate hollow fiber (CA9O, surface area 0.9 M2, Cobe Laboratory,
Inc., Lakewood, Colorado, USA). After one session of four
hours of routine clinical dialysis (using a blood flow rate of 200
to 250 ml/min), the blood compartment of the dialyzers was
immediately washed with 500 ml of normal saline. Next, the
dialyzers were rinsed with 2 liters of deionized water and
membrane-associated C3 fragments were analyzed as described
below.
Antibodies against C3 and C3 fragments
Polyclonal goat anti-human C3 IgG was purchased from
Atlantic Antibodies (Scarborough, Maine, USA). Affinity-puri-
fied anti-C3 was prepared by eluting specifically bound immu-
noglobulins from a column of C3-Sepharose using 4 M MgCl2.
Rabbit anti-human C3d IgG was purchased from DAKO Corp.
(Santa Barbara, California, USA). Affinity-purified monoclonal
anti-C3 antibodies were from Dr. Gordon Ross (University of
North Carolina School of Medicine, Chapel Hill, North Caro-
lina, USA). The clone 3 antibody (anti-C3d) recognizes an
epitope located in the C3d region of the molecule [25]. This
epitope is expressed by C3b, iC3b, C3dg, and C3d. The clone 4
antibody (anti-C3c) recognizes an epitope located in the C3c
region and expressed by C3b, iC3b and C3c. Monoclonal
antibodies were radiolabeled with 1251 as Nal (Amersham
Corp., Arlington Heights, Illinois, USA) to a specific activity of
5.0 to 12.2 x iO cpm/g using IODO-GEN (Pierce Chemical
Corp., Rockford, Illinois, USA) [26].
Isolation and characterization of C3 fragments
Human C3 was purified from fresh frozen plasma as de-
scribed elsewhere [27]. C3c and C3dg fragments were generated
in human serum following activation of complement by cobra
venom factor (naja naja) (Cordis Laboratories, Miami, Florida,
USA) and heat-aggregated IgG, essentially as described previ-
ously [28]. Complement-activated serum was applied to a
column of anti-C3-Sepharose (anti-C3-IA) (prepared using the
goat anti-human C3 IgG described above) pre-equilibrated to
pH 7.4 with EQB (50 m sodium phosphate/250 mM NaCl/5 mM
Na2EDTA). The outlet of anti-C 3-IA was directly connected to
a column of anti-C3d-Sepharose (anti-C3d-IA) (prepared using
the rabbit anti-human C3d IgG described above). Following
application of the sample, the columns were washed with EQB,
and the eluate (0.5 ml/tube) was monitored for protein content
(A280). When the absorbance approached zero, the columns
were disconnected and treated separately but simultaneously as
follows: (1) to elute non-immunologically bound proteins (pri-
marily albumin), the immunoadsorbent columns were washed
with 3 M NaC1 in EQB and then reequilibrated with EQB; (2)
the antigens were eluted with 1 M acetic acid, and the pH of the
eluates was adjusted to 7.4 with 2 M Tris-Base (Sigma Chemical
Co.) (to avoid detrimental effects of low pH, the immunoadsor-
bents were promptly washed with EQB); (3) the eluted antigens
were dialyzed in Spectropor dialysis tubing (Spectrum Medical
Industries, Inc., Los Angeles, California, USA) against three
changes of a 200-fold volume excess of PBS at 4°C; (4) the pools
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were concentrated by ultrafiltration with Diaflo PM 10 mem-
branes (Amicon Corp., Danvers, Massachusetts, USA); and (5)
analyzed by SDS-PAGE.
Preparative PAGE in the presence of 0.1% SDS was used to
separate C3dg monomer (Mr 40 kDa) and C3dg dimer (Mr
80 kDa), and to remove albumin and a polypeptide of Mr — 10
kDa. Conditions were essentially the same as those previously
described for the isolation of C3c and C4c [281. The eluates
were monitored by absorbance at both 220 nm and 280 nm, and
by analytical SDS-PAGE. The fractions containing the proteins
of interest were pooled and dialyzed against PBS as described
above, sterilized by passage through 0.22 m filters (Millipore
Corp., Bedford, Massachusetts, USA), and stored below 5°C.
In addition to SDS-PAGE analysis, the purified fragments were
also characterized by N-terminal sequence analysis, Western
blot analysis, and by double-immunodiffusion Ouchterlony as-
say using polyclonal rabbit anti-C3c and anti-C3d IgG.
Analysis of used cuprophan dialysis membranes with
monoclonal antibodies recognizing epitopes on C3c or C3d
fragments
New and used cuprophan membrane, hollow fiber dialyzers
which had been prepared as described above, were equilibrated
with PBS/A by recirculating 250 ml of PBS/A through the blood
compartment of the dialyzers from a beaker reservoir whose
temperature was maintained at 37°C. One jg of either radiola-
beled monoclonal anti-C3d or anti-C3c was diluted in 250 ml of
PBS/A and three 1 ml aliquots were reserved for subsequent
determination of radioactivity. The remaining buffer containing
the antibody was recirculated through the blood compartment
of the dialyzer at 37°C. After 30 minutes, the buffer containing
the unbound antibody was evacuated from the dialyzer by air
rinsing. The exact volume was measured, and in triplicate, the
radioactivity (cpmlml) was determined. In order to calculate the
percent of antibody which bound to the membrane, the total
number of counts in the buffer following the recirculation (cpm/
ml x final volume) was divided by the total number of counts in
the buffer prior to recirculation (cpm/ml x initial volume). This
value was subtracted from 1 and multiplied by 100.
Effects of formalin and sodium hypochlorite (NaOC1) on
membrane-associated C3
The blood compartment of used cuprophan, hollow fiber
dialyzers, which had been prepared as described above, was
infused with 60 ml of a 2% solution of formalin (0.75% formal-
dehyde) and left at 4°C for 24 hours. In separate experiments,
dialyzers rinsed with saline and deionized water were infused
with a 4% solution of NaOCl and subjected to continuous gentle
agitation for 50 seconds at RT. The formalin or NaOCl was
removed by washing the membranes with 10 liters of deionized
water, and binding studies using radiolabeled monoclonal anti-
C3d were performed as described above. For comparison,
parallel binding studies were performed on unused membranes
and used membranes that had not been subjected to treatment
with either formalin or NaOC1,
To determine if treatment with NaOCl regenerated the capa-
bility of used cuprophan membranes to bind activated comple-
ment, 60 ml of normal human serum were infused into the blood
compartment of used cuprophan dialyzers which had been
previously treated with NaOCl. After incubating for 30 minutes
at 37°C with continuous gentle agitation, the dialyzers were
washed and binding studies using radiolabeled anti-C3d were
performed as described above.
Analysis of C3 fragments associated with cuprophan sheet
membranes
In the binding studies described above, subsaturating
amounts of antibody were used. The quantity which would have
been required to perform the studies using saturating amounts
greatly exceeded the available supply. To overcome this prob-
lem, the sheet membrane from cuprophan plate dialyzers (PPD
1.6, surface area 1.6 M2, Cobe Laboratory, Inc.) were used.
Following four hours of routine clinical hemodialysis, the plate
dialyzers were washed with normal saline and deionized water
as described above for the hollow fiber dialyzers. Next, 2 X 2
cm2 squares were cut from the membrane sheets and incubated
with various concentrations of radiolabeled anti-C3d (from 0.1
g/ml to 1.0 g/ml diluted in PBS/A) at 37°C. Controls for
non-specific binding were 2 x 2 cm2 squares cut from sheets of
unused cuprophan membranes (from Dr. U. Baurmeister, Enka
AG, Wuppertal, FRG). After 30 minutes, the membranes were
extensively washed with PBS and the radioactivity was quan-
tified in a gamma counter. The amount of antibody bound at
each concentration was calculated by dividing the cpm/piece of
membrane by the specific activity of the radiolabeled antibody.
Specific binding was defined by the difference between the
radioactivity of the unused membranes and that of the used
membranes. The binding isotherms derived from these experi-
ments revealed a dose response curve that was concave from
the abscissa, consistent with a saturable reaction. There was no
statistically significant difference between the amount of anti-
body specifically bound at 0.5 jg/ml and that bound at 1.0 tg/
ml (data not shown). For this reason, 1 tg/ml was considered to
represent antibody excess, and this concentration was used in
the remainder of the experiments described below.
To determine if cuprophan membranes can bind more acti-
vated C3 following clinical use, sheet membranes were isolated
after four hours of routine hemodialysis. Next, cut pieces of the
used membrane were incubated with either 5 ml of normal
human serum (NHS) or PBS/A at 37°C. After 30 minutes, the
membranes were washed with PBS/A and incubated with 1 g/
ml of radiolabeled anti-C3d as described above. After washing,
the radioactivity of the membranes was quantified in a gamma
counter, and the antibody binding of the two groups was
compared.
To show that binding of C3d antigen-containing fragments
onto the cuprophan membrane surface required complement
activation, cut pieces of unused membranes were incubated at
37°C with 5 ml of NHS in the presence or absence of 20 mtvi
EDTA. After 30 minutes, the membranes were washed with
PBS/A and assayed for the presence of C3d antigens as de-
scribed above.
To examine the nature of the binding between the C3 frag-
ments and the dialysis membranes, the capacity of urea to elute
these fragments was studied. Cut pieces of new cuprophan
membranes were incubated with NHS as described above.
After washing, the membranes were incubated for 30 minutes at
37°C with 5 ml of 10 M urea, pH 7.0. Next, the membranes were
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washed and the binding of radiolabeled anti-C3d was quantified
as described above. To determine if the reduction in antibody
binding following urea treatment of new membranes which had
been exposed to NHS was a consequence of removal of C3
proteins or of destruction of the epitope recognized by the
antibody, the capacity of these membranes to activate the APC
was examined. Membranes that had been treated with NHS and
then urea were reexposed to NHS. After washing, the mem-
branes were incubated with radiolabeled anti-C3d, and mem-
brane associated radioactivity was subsequently quantified.
In order to determine if NaOCl affects the capacity of new
cuprophan membranes to bind C3d antigens, new membrane
sheets were incubated with 5 ml of either 4% NaOC1 or PBS at
RT. After 50 seconds, the membranes were washed and incu-
bated with 5 ml of NHS. Subsequently, binding of radiolabeled
anti-C3d was determined. The background for this group of
experiments was provided by incubation of the membrane with
EDTA-NHS rather than NHS.
Analysis of proteins eluted from cuprophan membranes with
hydroxylamine and/or urea by SDS-PAGE and Western blot
Cuprophan hollow fiber membranes that had been used for
four hours of routine clinical hemodialysis were immediately
washed with saline and water as described above. Non-cova-
lently bound proteins were eluted by recirculating 60 ml of 10 M
urea, pH 7.0 through the blood compartment of the dialyzer
from a beaker reservoir whose temperature was maintained at
37°C. After 120 minutes, the eluate was collected and concen-
trated to a final volume of 6 to 10 ml by ultrafiltration using an
Amicon 8200 stir cell concentrators (Arnicon Corp.) equipped
with a Diaflo PM 10 membrane (Amicon, Corp.) whose molec-
ular weight exclusion limit was 10 kDa. The A280 of the
ultrafiltrate was monitored and used as a measure of protein
loss resulting from the concentration procedure. To remove C3
fragments that were potentially covalently bound [16, 17, 29,
30], 60 ml of 1 M NH2OH, pH 10.5 was recirculated through the
blood compartment of a separate group of used dialyzers as
described above. After 30 minutes the eluate was recovered and
concentrated. Sequential elution with urea and NH2OH was
accomplished by first treating the membrane with 10 M urea, pH
7.0 as described above. After recovering the eluate, the mem-
brane was treated with 1 M NH2OH, pH 10.5, and the eluates
were concentrated separately as described above. Next, the
concentrated eluates were dialyzed against three changes of 2
liters each of PBS at 4°C using Spectropor membrane tubing
(Spectrum Medical Industries, Inc.) whose molecular weight
exclusion limit was 2 kDa. The samples were analyzed by
SDS-PAGE under reducing conditions using a 5 to 15% linear
gradient gel. Each well contained 30 tg of protein. The gels
were fixed and stained with Coomassie blue as previously
described [31].
For analysis by Western blot, the eluates were subjected to
SDS-PAGE under reducing conditions as described above and
then electrophoretically transferred to nitrocellulose paper
(Trans-Blot Transfer Medium, Bio-Rad Laboratories, Rich-
mond, California, USA). The paper was incubated with TBS-
milk for 30 minutes. After being washed three times with TBS,
the paper was incubated with 50 ml of TBS-milk containing 50
sg of goat anti-human C3 IgG for two hours at RT. Next, the
paper was washed three times with TBS and incubated for two
hours at RT with TB S-milk containing 50 g of affinity-purified,
peroxidase-conjugated porcine anti-goat IgG (Tago, Inc., Bur-
lingame, California, USA). After washing with TBS, the posi-
tion of the antibody binding was identified by incubating the
paper with 50 ml of TBS containing 50 mg of 3, 3'diamino-
benzidine (Sigma Chemical Co.) and 50 l of 30% H202. The
development was stopped after five minutes by discarding the
supernatant and adding 50 ml of 1 M NH4OH. After washing
with deionized water, the sheet was air dried and photographed.
Eluates were also analyzed by Western blot for the presence
of proteins which expressed C3d epitopes. In these experiments
rabbit anti-human C3d IgO was used as the primary antibody
and affinity-purified, peroxidase-conjugated anti-rabbit IgG
(Tago, Inc.) was used as the secondary antibody. Molecular
weight estimates were calculated according to the method of
Weber and Osborne [32] using molecular weight standards
purchased from Bio-Rad Laboratories (Richmond, California,
USA), and the established Mr for the a and f3 chains of C3 (125
and 75 kDa, respectively), the 43 and 40 kDa fragments of the a
chain of C3c, C3dg (41 kDa), and C3d (33 kDa).
Characterization of eluates from cuprophan and cellulose
acetate membranes by Western blot analysis
To compare the forms of C3 associated with cuprophan and
cellulose acetate, four cuprophan and four, cellulose acetate
hollow fiber dialyzers from eight different patients following
four hours of clinical dialysis were eluted with I M NH2OH as
described above. After concentration and dialysis, the eluates
were frozen at —70°C. The patients were then switched to
dialysis with the other type of membrane. After two weeks of
routine dialysis, a used membrane from each patient was eluted
with 1 M NH2OH and the eluates were concentrated and
dialyzed. The exact volumes of the concentrated and dialyzed
eluates were measured. An aliquot of each eluate was then
subjected to analysis by Western blot using either goat anti-
human C3 or rabbit anti-human C3d as the primary antibody.
Another aliquot of each eluate was subjected to C3 quantitation
by ELISA as described below.
Quantitative comparison of the C3 fragments eluted from
cuprophan and cellulose acetate membranes by
enzyme-linked immunosorbent assay (ELISA)
A two-step competitive ELISA [331 was used to quantify C3
fragments. In the C3 ELISA, the wells of microtitre plates
(Nunc-Immuno Plate, A/S Nunc, Roskilde, Denmark) were
incubated with 200 pJ of purified C3 (0.625 g/ml in 0.1 M
NaHCO3) overnight at 37°C. The plates were washed three
times with PBS-Tween. Aliquots of the eluates were diluted to
three different protein concentrations of 100, 50 and 25 ig/ml,
respectively, with PBS-Tween. Dilutions of purified C3 (0.06 to
31.25 tg/m1 in PBS-Tween) were used to generate a standard
curve. Affinity-purified goat anti-human C3 that had been
peroxidase conjugated according to the method of Nakane and
Kawaoi [341 was diluted to 0.4 pg/ml with PBS-Tween. This
antibody was mixed (1: 1 vol/vol) with the dilutions of the
eluates and of the purified C3. Two hundred l of these
mixtures were pipetted into microtitre wells and incubated for
two hours at RT. Next, the plates were washed five times with
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PBS-Tween and 100 d of chromogenic reagent (0.4 mg/mI of
o-phenyldiamine and 0.01% H202 in 0.1 M citrate/phosphate
buffer, pH 5.0) was added to each well. The plates were
incubated for 15 minutes at RT in the dark and 100 s1 of 4 N
H2S04 was added to stop the reaction. The A492 was measured
using a Titertek Multiskan MCC spectrophotometer (Flow
Laboratories Inc., Santa Barbara, California, USA). A standard
curve was developed by plotting the logarithm of the concen-
tration of purified C3 per dilution versus the A492 of the dilution.
The concentration of C3 fragments in the samples were derived
from the standard curve. The average of the values derived
from the three different dilutions was taken as the concentration
of each eluate. The amount of C3 fragments eluted from each
membrane was calculated by multiplying the concentration by
the total volume of the eluate.
The C3d ELISA was performed in the same fashion as that
described above for the C3 ELISA with the following modifi-
cations: (1) the wells were initially incubated with 200 d of
purified C3 at 10 sg/ml; (2) the dilutions of purified C3 used to
generate the standard curve ranged from 0.48 to 62.5 sgIml; (3)
the peroxidase-conjugated antibody was rabbit anti-human C3d
(which had not been affinity-purified), and it was used at a
concentration of 1.25 g/ml; (4) the eluates were diluted to
protein concentrations of 500, 250 and 125 sg/ml. Inasmuch as
C3 instead of C3d was used in the standard curve to inhibit the
binding of the peroxidase conjugated anti-C3d, the values for
the eluates are expressed in inhibitory units. One inhibitory unit
would produce the same A492 as 1 jg/ml of C3.
Protein concentrations
The protein concentration of purified C3 was determined
spectrophotometrically [35]. The concentration of C3c and
C3dg was estimated using an absorption coefficient of 280 nm of
10.0. The protein concentration of the eluates was determined
by Bio-Rad Protein Assay (Bio Rad Laboratories) using bovine
IgG as the standard.
Statistical analysis
Unpaired data was analyzed by Student's f-test.
Results
Detection of C3 activation products associated with used
cuprophan dialysis membranes
To determine if fragments of activated C3 become associated
with cuprophan membranes during dialysis, binding of two
monoclonal antibodies to new and used dialyzers was quanti-
fied. The anti-C3c (clone 4) employed in these experiments
recognizes an epitope expressed by C3b, iC3b, and C3c (but not
by C3dg or C3d) while the anti-C3d (clone 3) recognizes an
epitope expressed by C3b, iC3b, C3dg, and C3d (but not by
C3c). The amounts of anti-C3c and anti-C3d that bound to the
membranes were equivalent (Table 1). In these experiments,
subsaturating amounts of antibody were used, inasmuch as
binding experiments performed with 20 times more radiolabeled
antibody gave results similar to those reported in Table 1 (that
is, 60 to 70% of the radiolabeled antibody bound to the
membrane, indicating that 60 to 70% of the affinity-purified
radiolabeled antibody was functionally active). These experi-
ments demonstrate that C3 activation products are associated
Table 1. Binding of two monoclonal anti-C3 antibodies to cuprophan
hollow fiber dialyzers
Type of
membrane
AntiC3da
bound
Anti-C3c1'
bound
NewC 16.2 0.7% 17.4 1.5%
Used" 66.5 2.7%e 69.5 2.7%e
This antibody recognizes an epitope which is expressed by C3b,
iC3b, C3dg and C3d but not by C3c. The results arc presented as the
mean SEM (n = 4).
b This antibody recognizes an epitope which is expressed by C3b,
iC3b and C3c but not by C3dg or C3d. The results are presented as the
mean 5EM (n = 4).
C Membranes which had never been used for clinical dialysis.
d Membranes which had been employed for 4 hours of routine clinical
hemodialysis.
e These values are significantly different compared to those of the
corresponding new dialyzers (P < 0.001).
with used cuprophan membranes and that C3 is not present
exclusively as C3c or C3d (or C3dg). Since the amount of
antibody was limiting, however, and since there is overlap in
the forms of C3 recognized by the two antibodies, these results
cannot be used to determine the quantity or the exact forms of
C3 fragments that are associated with the membranes.
Effects of NaOC1 on membrane-associated C3
Formalin and NaOC1 are the two most commonly used
sterilants for the processing of reused dialyzers. The latter
reagent restores the complement activating potentials of the
used membranes, whereas the former does not. To determine if
NaOCI removed membrane-associated C3 fragments, used cu-
prophan membranes were treated with NaOCl, and after exten-
sive washing, binding of radiolabeled anti-C3d was quantified.
Treatment with NaOCl resulted in markedly less antibody
binding to the used membrane (Fig. 1). Since 60 to 70% of the
radiolabeled antibody is active, and since the NaOCI-treated
membranes bound approximately 25% of the available anti-
body, in this portion of the experiment, antibody was present in
excess. As noted above, even 20 times the amount of antibody
(20 g) employed in these experiments will not saturate the
available antibody binding sites on used membrane in the intact
dialyzers. Taken together, these observations suggest that
NaOC1 removes >99% of the membrane-associated C3d anti-
gens. [This estimate was derived by subtracting the non-specific
binding (binding to unused membranes = 16%) from the binding
to used membrane (65%), and this value (49%) was multiplied
by 20 (980%). Next, non-specific binding was subtracted from
binding to the NaOCl-treated membrane (25 — 17 = 8%) and
this value was divided by 960% = 0.008]. When used mem-
branes were treated with NaOC1 and then re-exposed to normal
human serum, the amount of antibody that bound to the
membrane was equivalent to that which bound to used mem-
branes (Fig. 1). The results of this experiment demonstrate that
treatment with NaOCl removes membrane-associated C3,
thereby restoring the capacity of the used membrane to bind C3
and activate complement.
In contrast to the above results observed following treatment
with NaOC1, incubation of used cuprophan, hollow fiber dialy-
zers with 2% formalin did not affect the amount of anti-C3c or
anti-C3d that bound to the membranes (data not shown).
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Fig. 1. Effect of NaOCI on the binding of radiolabeled monoclonal
anti-C3d antibody to intact cuprophan membrane, hollow fiber dialy-
zers. (1) Unused (new) membranes which were washed with saline,
deionized water and PBS/A. (2) Membranes which had been employed
for four hours of clinical dialysis, then washed with saline, deionized
water, and PBS/A (used). (3) Used membranes washed with saline and
deionized water, exposed to a 4% solution of NaOCI, then washed with
deionized water and PBS/A (used + NaOCI). (4) Used membranes
treated with NaOCI and washed, then incubated with normal human
serum (Used + NaOCI + NHS). The radiolabeled antibody was
recirculated through the blood compartments of the dialyzer, and the
amount that bound was calculated as described in the Methods section.
Results are depicted as the mean SEM (N = 4). *p < 0.001 vs. new,
**p < 0.001 vs. used, ***p < 0.001 vs. used + NaOCI. Treatment of
used membranes with NaOCI abbrogated antibody binding, while
exposure of NaOCl-treated used membranes to NHS restored antibody
binding activity. These results suggest that NaOCI removes C3 frag-
ments and restores the complement activating potential of the mem-
branes.
Analysis of C3 fragments associated with cuprophan sheet
membranes
The decreased binding of anti-C3d to the used cuprophan
membranes following treatment with NaOCI (Fig. 1) could be
due, not to removal of C3, but rather to a change in the
biochemical properties of the membrane-associated C3 such
that the molecule is no longer recognized by the antibody. The
restoration of antibody binding following subsequent reexpo-
sure of the NaOCl-treated membrane to NHS could then be
explained if the clinically used membrane was either not satu-
rated with molecules expressing C3d or if NaOCl enhanced the
complement activating potential of the membrane. To investi-
gate these hypotheses, binding experiments in which the mono-
clonal antibodies were present in excess were performed using
isolated pieces of cuprophan sheet membranes (2 X 2 cm2
surface area).
Following use in routine clinical dialysis, pieces of membrane
bound an average of 90 ng of radiolabeled anti-C3d, an amount
which represents less than 10% of the total antibody input (Fig.
2A). When pieces of used membrane were subsequently incu-
bated with NHS, the amount of antibody which bound to the
membrane was not statistically different from that which bound
to used membranes that had not undergone in vitro exposure to
serum. These results demonstrate that cuprophan membranes
have a finite capacity for activating and binding C3, and that
during use in clinical dialysis, the available binding sites be-
come saturated.
To determine if NaOC1 increased the capacity of the mem-
brane to bind activated C3, antibody binding to pieces of new
cuprophan membrane that had been pretreated with NaOCl and
then exposed to NHS was quantified. There was no difference
in the amount of antibody that bound to membranes pretreated
with NaOCI compared to that which bound to untreated mem-
branes (Fig. 2B). These results demonstrate that NaOCI does
not enhance the capacity of new cuprophan membranes to
activate the APC and bind C3. In conjunction with the data
presented in Figure 2A, these observations are consistent with
the hypothesis that the decrease in antibody binding to used
membranes treated with NaOC1 is due to removal of membrane-
associated C3, and that removal of proteins by NaOCl restores
the complement activating potential of the membrane.
The amount of antibody bound to the membrane pieces
following exposure to EDTA-chelated serum was no greater
than binding to membranes that had not been exposed to serum
(Fig. 2C). These experiments demonstrate that molecules which
express C3d antigens do not bind to cuprophan membranes in
the absence of complement activation.
To examine the nature of binding between the C3 fragments
and the membranes, pieces of cuprophan membranes that had
been incubated with serum were washed and then exposed to 10
M urea at neutral pH. Under these conditions, covalently bound
C3 fragments are not eluted [16]. Subsequent antibody binding
studies using radiolabeled anti-C3d showed that treatment with
urea abolished the binding of anti-C3d (Fig. 2D). These results
could be due to removal of C3 or to denaturation of the epitope
recognized by the antibody. To distinguish between these two
possibilities, membranes that had been exposed to NHS and
then to urea were re-exposed to serum, and anti-C3d binding
was subsequently quantified. These experiments showed that
antibody binding to the reexposed membrane was not signifi-
cantly different from binding to new membranes that had been
exposed to NHS (Fig. 2D). Inasmuch as the membranes have a
finite capacity to activate and bind C3 (Fig. 2A), these findings
indicate that urea removed the non-covalently bound proteins,
and consequently restored the complement activating potential
of the membranes.
That 10 M urea at neutral pH does not destroy the epitope
recognized by the monoclonal anti-C3d was substantiated by
immunoblotting experiments. Following incubation of purified
C3dg with urea or with buffer under conditions identical to
those used for treatment of the membranes, the proteins were
subjected to SDS-PAGE. Subsequent analysis by Western blot
and autoradiography showed that the binding of radiolabeled
anti-C3d to urea treated and sham treated C3dg was equivalent
(not shown).
In summary, since the monoclonal anti-C3d recognizes all
forms of C3 that have the potential to be covalently bound,
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Fig. 2. Binding of radiolabeled monoclonal anii-C3d antibody to pieces of cuprophan sheet membranes. Two X 2 cm2 pieces ofmembranes were
isolated from unused sheet dialyzers (new) or from sheet dialyzers which had been used in clinical hemodialysis (used). After treatment (as
described below), the sheets were washed and incubated with radiolabeled anti-C3d and antibody binding was determined as described in the
Methods section. The values are presented as mean SEM (N = 4 to 9). *These values are significantly higher when compared to the values for
new membranes (P < 0.01). A. Used pieces of membranes were washed and incubated with PBS (used) or NHS (used + NHS). The difference
in the amount of antibody bound to used vs. used + NHS was not statistically different (P > 0.05). These results suggest that the capacity of
cuprophan membranes to activate complement and bind C3 is finite, and that maximum capacity is reached during four hours of clinical dialysis.
B. New membranes were treated with PBS or4% NaOCI, then washed and incubated with NHS. The difference between the amount of antibody
bound to new + PBS + NHS vs. new + NaOCI + NHS was not statistically significant (P > 0.05). These results suggest that exposure of
duprophan membranes to NaOCI does not enhance the complement activating potential of the membrane, the C3 binding capacity, or the antibody
binding capacity. C. New membranes were incubated with PBS or EDTA-NHS. Binding of anti-C3d to the two sets of treated membranes was not
statistically different suggesting that the deposition of C3d antigens Onto the membrane surface requires complement activation. D. New
membranes which had been incubated with NHS (new + NHS) bound significantly more anti-C3d than new membranes incubated with PBS. When
new membranes which had been incubated with NHS were treated with 10 M urea, pH 7.0 (new + NHS + urea), subsequent antibody binding
decreased to an amount which was not statistically different from that observed for new membranes. After such urea-treated membranes were
re-exposed to NHS (new + NHS + urea + NHS), the amount of antibody bound to these membranes was not statistically different (P> 0.05) from
that bound to membranes which had been exposed to NHS without urea treatment. These data show that C3d antigens on the membrane surface
are effectively removed by urea and suggest that membrane-associated C3 fragments are not covalently bound.
these experiments suggest that C3 activation products are not
covalently bound to the membrane.
Characterization of proteins eluied from cuprophan
membranes with hydroxylamine and/or urea by SDS-PAGE
and Western blot analysis
To analyze further the C3 fragments associated with used
cuprophan dialyzers, membrane-associated proteins were elu-
ted using I M NH2OH at alkaline pH (Fig. 3A, lane c), or 10 M
urea at neutral pH (Fig. 3A, lane d) followed sequentially by
NH2OH (Fig. 3A, lane e). The urea dissociates non-covalently
bound proteins, while the NH2OH is used to elute covalently
bound C3 fragments by neucleophilic attack on oxygen ester
bonds.
The predominant protein eluted by both NH2OH and urea
has an electrophoretic mobility similar to that of human serum
albumin (Mr = 66 kDa; Fig. 3A, lanes c, d and e). Despite the
fact that albumin is not covalently bound, it was incompletely
removed from membrane of intact dialzyers by urea as evi-
denced by the fact that subsequent treatment of the membrane
with NH2OH removed additional albumin (Fig. 3A, lane e
compared to lane d). These results also indicate that NH2OH at
alkaline pH removes non-covalently bound proteins more effi-
ciently than urea. A protein whose M1 was estimated to be 54
kDa is visible in lanes c and d. The molecular weight is
consistent with that of the heavy chain of IgG, and this protein
is eluted by both NH2OH and urea. The f3 chain of C3 is visible
in lane d as well as in lanes c and e, indicating that at least some
of the C3 that is associated with the membrane is non-cova-
lently bound.
To establish the identity of the C3 fragments associated with
the membrane. eluates, which had been prepared in the same
fashion as those described above, were subjected to analysis by
SDS-PAGE and Western blot. The antibody (polyclonal anti-
C3) used to develop the blot (Fig. 3B) recognizes epitopes
expressed on both the a and /3 chains of native C3 (lane a). C3c
(lane b) consists of the /3chain and of cleavage fragments of the
a chain of iC3b [36]. Enzymatic degradation of the a by factor
New
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Fig. 3. Analyses by SDS-PAGE and Western blot of proteins eluted
from cuprophan hollow fiber dialyzers. The dialyzers, which had
been employed for clinical dialysis for 4 hours, were rinsed with
normal saline and deionized water. The proteins on the membrane
surface were eluted using I M NH,OH, pH 10.5 (NH2OH eluate). In
addition, proteins from a different cuprophan dialyzer were eluted
sequentially first using 10 M urea, pH 7.0 (urea eluate), followed by 1
M NH,OH (NH,OH eluate following urea). The eluates were
concentrated, dialyzed against PBS and analyzed by SDS-PAGE(reducing condition) and Western blot. A detailed interpretation ofC3cs— the data is provided in the Results section. A. SDS-PAGE stained
with Coomassie blue. The positions of the molecular weight markers
are indicated on the left of the photograph of the gel. Lane a, isolated
C3 (I pg). The positions of the a and /3 chains are indicated on the
left. Lane b, isolated C3c (I pg). The position of the /3 chain and of
a43 are indicated on the left. Lane c, NH2OH eluate (30 pg). Lane d,
urea eluate from a different used cuprophan dialyzer (30 pg). Lane e,
NH2OH eluate following urea (30 .tg). B. Western blot developed
using polyclonal anti-C3 as the primary antibody. The lanes were
loaded with the same amount of protein as described in Panel A. The
41 kDa— positions of the a and /3 chains of C3, of a43 and of a40 are indicated
on the left. The location of the 27 kDa marker was derived from the
31 kDa relative electrophoretic mobility of the molecular weight marker (A).
C. Western blot developed using polyclonal anti-C3d as the primary
antibody. The lanes were loaded with the same amount of protein as
described in A. The position of the a chain of C3 is indicated on the
left. The locations of the 41 and 31 kDa markers were derived from
the relative electrophoretic mobility of the molecular weight markers
(A).
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I produces cr43 and/or cr40, and cr27. The antibody recognizes
cr43 (and cr40) but apparently not a27. The C3c standard used in
these experiments appears to contain no cr40.
The C3 eluted with NH,OH is almost exclusively in the form
of C3c (Fig. 3B, lane c). There is no observable a chain of C3,
C3b or iC3b (cr68), indicating that no unactivated C3 is associ-
ated with the membrane and that essentially all of the mem-
brane-associated C3 has been cleaved beyond the iC3b stage
(into C3c and C3d/C3dg). In this particular case, cr40 predomi-
nated over cr43, however, analysis of other eluates demon-
strated that this was not a consistent finding (Fig. 4A). A band
was observed in a position Consistent with cr27, however,
inasmuch as cr27 was not seen in the lane containing the C3c
standard, it seems more likely that this band (and the other
bands whose Mr is less than 40 kDa) are degradation products
of cr43/40.
When a cuprophan dialyzer was treated with 10 M urea at
neutral pH, C3c was again the predominant form of C3 eluted
(Fig. 3B, lane d). This finding was anticipated since C3c does
not contain the thiolester group and therefore cannot be cova-
lently bound. When this same cuprophan membrane was
treated with NH2OH following the initial treatment with urea,
more C3c was eluted (Fig. 3B, lane e). In this eluate, both cr43
and cr40 were observed. These experiments demonstrated that
NH,OH at alkaline pH is more efficient in dissociation of
non-covalently bound C3 fragments from the membrane than 10
M urea at neutral pH.
To determine if any C3 fragments containing C3d epitopes
were eluted with NH,OH or urea, Western blots were devel-
oped with polyclonal anti-C3d. The antigenic sites recognized
by the antibody are expressed on the intact cr chain of native C3
(Fig. 3C, lane a). C3c does not contain the C3d region of the cr
chain, and thus the anti-C3d does not recognize isolated C3c
(Fig, 3C, lane b). Isolated C3dg and C3d were not available for
use as standards in these experiments, however, Figure 4B,
lane b, shows that these two fragments are recognized by the
antibody. Treatment of used cuprophan membranes with
NH,OH eluted a relatively small amount of protein that was
recognized by the antibody (Fig. 3C, lane c). The exact com-
position of these proteins is uncertain: however, they most
likely represent monomers and multimers of C3d/C3dg and
proteolytic cleavage products of these derivatives. Urea eluted
in trace amounts a protein whose electrophoretic mobility is
consistent with C3d (Fig. 3C, lane d). Subsequent treatment of
the membrane with NH,OH eluted more protein recognized by
the anti-C3d antibody (lane e). It is conceivable that all of these
C3d/C3dg fragments in lane e were covalently bound; however,
as seen in previous experiments, NH,OH eluted non-covalently
bound proteins more effectively than urea (Fig. 3B, lane e
compared to lane d). Further, at least some of the membrane-
associated C3d fragments could be eluted with urea (Fig. 3C,
lane d), indicating that they were not covalently bound. For this
reason, the amount of C3d/C3dg related fragments that were
covalently bound cannot be determined from these particular
experiments. In addition, compared to C3d/C3dg, much more
C3c is membrane-associated (Fig. 3B vs. Fig. 3C). Since C3c
and C3d/C3dg are produced in equimolar amounts upon degra-
dation of iC3b, it appears that much of the C3d that is generated
during hemodialysis does not remain associated with the mem-
brane.
Comparison of c/ito tes from cuprophan and cellulose acetate
membranes using Western blot analysis
Cellulose acetate membranes support less complement acti-
vation than cuprophan membranes. To determine if C3 mole-
cules were present on the membranes in the same or different
forms, C3 fragments eluted by I M NH2OH, pH 10.5 from
paired membranes (Methods) were characterized by SDS-
PAGE and Western blot analysis. The polyclonal anti-C3 used
to develop the blot shown in Figure 4A recognizes epitopes
expressed on the a and /3 chains of native C3 (lane a) and
isolated C3c (lane c), but it does not recognize antigenic sites in
the C3d region of the a chain (lane b). For both cellulose acetate
and cuprophan membranes, the predominant form of C3 eluted
was C3c. The molecular composition and apparent amount of
C3 eluted from the two types of membranes did not follow a
consistent pattern.
When the blots were developed with anti-C3d (Fig. 4B),
relatively minor amounts of C3d-related proteins were ob-
served. Again, the forms of C3d eluted from the two types of
membranes varied among the different patients. Furthermore,
the amount of C3d eluted also appeared to be independent of
the type of membrane employed. These experiments suggest
that the forms and amounts of membrane-associated C3 frag-
ments do not distinguish the complement activating potential of
the dialyzers.
Quantitative comparison by ELISA of the C fragments
eluted from cuprophan and cellulose acetate membranes
The amount of C3 fragments associated with the dialyzer
membranes of eight patients was quantified using two ELISAs
(Fig. 5). There was no statistically significant difference be-
tween the amount of C3 or C3d antigen which was eluted from
the two types of membranes. When the blood compartment of
the cuprophan hollow fiber dialyzers were rinsed with 60 ml of
I M NH,OH, pH 10.5, for four more hours, an additional 11%
of C3 antigen-containing molecules could be recovered. This
indicates that most of the elutable C3 fragments on the mem-
branes were removed during the first 30 minutes of incubation
with NH2OH. These experiments demonstrate that there is no
difference in the capacity of cellulose acetate and cuprophan
membranes to bind activated C3.
Discussion
These studies suggest that the complement activating poten-
tial of cellulosic dialysis membranes is not determined primarily
by the availability of covalent binding sites for activated C3b.
The predominant form of C3 associated with both cellulose
acetate and cuprophan membranes is C3c (Fig. 4A), a degrada-
tion fragment of activated C3b which cannot be covalently
bound since it lacks the thiolester group that mediates ester
bond formation between metastable C3b and an acceptor sur-
face [37]. A modest amount of C3d (a degradation fragment of
activated C3b that does contain the thiolester group) (Fig. 4B) is
also associated with the membranes. While a relatively small
amount of C3d can be eluted from intact cuprophan hollow fiber
dialyzers with urea at neutral pH, a greater amount is eluted
with I M NH2OH at alkaline pH (Fig. 3C, lane d compared to
lane e). These results could be interpreted to indicate that most
of the C3d is covalently bound since NH2OH would provide a
AC3a (126 kDa)
C33 (75 kDa}—'-
B
a43 -
a40
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source for nucleophilic attack on oxygen ester bonds. As seen
in Figures 3A, and 3B, however, NH2OH is more effective than
urea in removing non-covalently bound proteins (albumin and
C3c). Thus one cannot conclude that C3d that is eluted by
NH2OH but not by urea is covalently bound. Indeed, the fact
that the C3d-related antigens can be completely removed from
cuprophan sheet membranes by treatment with urea suggests
that essentially all forms of membrane-associated C3 are non-
covalently bound (Fig. 2D).
It has been demonstrated previously that the APC is acti-
vated immediately after beginning dialysis with cuprophan
membranes [2, 4, 5, 9, 22]. Plasma C3a concentration reaches a
peak at 15 minutes and declines thereafter. It has been sug-
gested that the decline in APC activity results when the
Fig. 4. Analysis by Western blot of NH2OH
eluates from used cuprophan (Cu) and
cellulose acetate (CA) dialyzers. The eluates
were obtained by treating membranes used in
clinical dialysis with NH2OH, pH 10.5. The
eluates were concentrated, dialyzed against
PBS and analyzed by Western blot. The SDS-
PAGE was performed under reducing
conditions. A detailed interpretation of the
data is provided in the Results section. A.
Western blot developed using polyclonal anti-
C3 as the primary antibody. The positions of
the a and /3 chains of C3 and their estimated
Mr are indicated on the left along with the
positions of a43 and a40 of C3c. Lane a,
isolated C3 (1 pg); lane b, isolated C3dg (I
sg); lane c, isolated C3c (1 sg). Lanes d to i
each contained 30 jtg of protein. H. Western
blot developed using polyclonal anti-C3d as
the primary antibody. The positions of the a
chain of C3, of C3dg, and of C3d and their
respective estimated M are indicated at the
left. The lanes contained the same amount of
protein as described in A.
available covalent binding sites for C3b become occupied [2,
24]. A similar hypothesis has been proposed to explain the
difference in complement activating potential between cupro-
phan and cellulose acetate membranes. As is the case with
cuprophan membranes, APC activation begins immediately
after starting dialysis with cellulose acetate membranes [22, 23].
With the latter membranes, however, C3a concentration
reaches a peak within five minutes. It has been suggested that
cellulose acetate membranes support less APC activation than
cuprophan membranes because they have fewer C3b binding
sites, since a portion of the hydroxyl groups have been acety-
lated [22, 241. The results of the studies reported here are
inconsistent with these hypotheses. First, as noted above, the
majority of the membrane-associated C3 fragments does not
C3 C3dg C3c Patient 1 Patient 2
Cu CA Cu CA
Patient 3
Cu CA
C d e t g h
C3 C3dg Patient 1 Patient 2 Patient 3
— —. —
Cu CA Cu CA Cu CA
h
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Fig. 5. Quantitation by ELISA of C3 eluzed from used cuprophan (Cu)
and used cellulose acetate (CA) membranes. Cuprophan and cellulose
acetate hollow fiber dialyzers were obtained following 4 hours of
clinical dialysis, and membrane-associated proteins were eluted with I
M NH2OH, pH 10.5. The total amount of C3 and C3d antigens eluted
were quantified using a competitive ELISA. Peroxidase-conjugated
polyclonal anti-C3 and anti-C3d were used to develop the assay. The
results of the C3d ELISA are expressed in inhibitory units (i.u.) since
C3 rather than C3d was used to establish the standard curve (details are
given in the Methods section). There was no statistically significant
difference between the amount of C3 and C3d antigens eluted from the
two types of membranes (N = 8, P> 0.05).
appear to be covalently bound, and second, the amount of C3c
and C3d associated with cuprophan and cellulose acetate mem-
branes is equivalent (Fig. 5). Thus, neither the mechanism of
binding nor the amount of activated C3 bound accounts for the
difference in APC activating potential between cellulose acetate
and cuprophan membranes.
On activator surfaces, such as zymosan or rabbit erythro-
cytes, the formation and stability of the APC C3 convertase is
initially favored because the binding affinity of factor B for a
portion of the membrane-associated C3b is greater than that of
factor H [11], As APC activation continues, the biochemical
properties of the membrane are changed such that the binding
affinity of factor H is enhanced, and, as a result, the activator
surface is eventually converted into a non-activator [381. The
observed interactions between complement and cellulose ace-
tate and cuprophan membranes suggest that these cellulosic
membranes may behave as APC activators. First, as noted
above, complement activation on cuprophan membranes de-
clines following an initial period of activation, and at the
completion of dialysis, essentially all of the membrane-associ-
ated C3b has been degraded to the inactive forms (C3c and C3d)
(Figs. 3B and C). The fact that this degradation process requires
the cofactor activity of factor H implies that all membrane-
associated C3b eventually binds factor H. These observations
are consistent with the concept that complement activation
modifies the biochemical properties of the dialyzer membrane,
thereby converting it from an APC activator into a non-
activator. Second, previous studies by Varki and Kornfeld [39]
have demonstrated that acetylation of carbohydrates on the
murine erythrocyte membrane modulates the functional activity
of the APC. While the carbohydrate moiety appears to be
•2000 principally responsible for determining the APC activating
potential of a surface, its influence is primarily on the functional
activity of the complement proteins which control the formation
and stability of the C3 convertase rather than on regulation of
binding of nascent C3b to the membrane surface [40]. Because
of these observations, it seems reasonable to postulate that
cellulose acetate membranes activate less complement than
1000 cuprophan membranes, not primarily because covalent bindingD sites for C3b are blocked by acetylation, but rather because
8 acetylation alters the biochemical properties of the membrane
so as to favor factor H binding to C3b. Also in favor of the
hypothesis that modification of hydroxyl groups does not atten-
uate APC activation by blocking binding sites for C3b is the
observation that Hemophan® (Enka) membranes activate little
complement [41]. On this type of cellulosic membrane only one
in every 150 hydroxyl groups is modified by the addition of a
diethylaminoethyl group.
Although covalent binding of activated C3b does not appear
to modulate the activity of the APC, the studies reported here
strongly support the concept that complement activation, and
the subsequent binding of plasma proteins, alters dialysis mem-
branes in such a way that they no longer supports APC
activation. Whether the biochemical modifications depend upon
binding of C3 fragments only or upon the binding of other
plasma proteins cannot be determined from these experiments.
Further, the mechanism by which complement activation con-
verts activators surfaces into non-activators is unclear. Cluster-
ing of C3b around a convertase site appears to enhance the
binding of factor H [26], and the studies reported here demon-
strate that removal of proteins by treatment with NaOCI
regenerates the complement activating potential of the mem-
brane (Fig. 1). It seems possible that deposition of C3 fragments
onto the membrane surface in a non-random fashion (that is,
clustered around convertase sites) may enhance factor H bind-
ing, thereby attenuating the activity of the APC. Subsequent
treatment with NaOCI would remove the non-covalently bound
C3 fragments and restore the original biochemical properties of
the membrane. In support of the hypothesis that activated C3 is
bound to the dialysis membranes in a non-random fashion is the
fact that C5a is generated during dialysis [1, 2]. Formation of
the CS convertase of the APC requires that two molecules of
C3b be bound in close proximity [101. The effects of non-
complement proteins which are adsorbed onto the membrane
surface (such as albumin) on the functional activity of the APC
also remain to be determined.
The exact nature of the non-covalent binding of C3 has not
been defined, however, the interactions with the membrane
appear to involve primarily the C3c domain of the molecule,
inasmuch as it is the predominant fragment which remains
associated with the membrane. Since degradation of iC3b
produces equimolar amounts of C3c and C3d, most of the C3d
which is generated as a result of degradation of membrane-
bound C3b must be washed away during clinical hemodialysis
and/or during preparation of the blood compartment for ex vivo
analysis. Preliminary experiments suggest that the amount of
C3 fragments associated with erythrocytes taken from patients
at various time points during and after hemodialysis is not
different from that associated with erythrocytes from normal
volunteers (data not shown). Further, it appears that only a
small part of the C3 which is activated during dialysis remains
nfl,',,
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firmly bound to the membrane. It can be estimated from
previous studies that approximately 5 to 7 .tmoles of C3a are
generated during the four hours of hemodialysis [2, 42]. Assum-
ing that C3a and C3c are formed on an equimolar basis, we
calculate that approximately 700 to 1000 mg of C3c (Mr 143
kD) are formed during the same period. Data from the ELISA
(Fig. 5) indicate that only 1.5 mg of C3 antigens remain
associated with the membrane, and most of these C3 antigens
are in the form of C3c (Fig. 3B). Thus, it appears that less than
1% of the activated C3 remains bound to the membrane after
clinical dialysis.
The studies reported here demonstrate that the greater acti-
vation of the APC by cuprophan dialyzers compared to cellu-
lose acetate dialyzers is not determined primarily by quantita-
tive or qualitative differences in the binding of activated C3
fragments. The molecular basis for these differences in comple-
ment activating potential remains to be elucidated, however,
preliminary data suggest that acetylation of cellulosic mem-
branes greatly influences the binding of the alternative pathway
regulatory proteins factors B and H [43]. An understanding of
the biochemical/biophysical properties of extracorporal mem-
branes which influence complement regulation should lead to
development of artificial membranes with improved biocompat-
ability.
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